Dr Fragkou holds a PhD in Electrochemical Biosensors from Cranfield University. She has prior to AegirBio worked in leading roles and has a proven background and expertise in the development of in-vitro diagnostic medical devices from its inception to successful launch.
Dr. Fragkou's leadership as COO will strengthen the company's position as an industry leader, driving innovation, and ultimately benefiting patients and healthcare providers alike. Dr. Fragkou will replace Dr Nils Paulsson.
CEO Marco Witteveen states; “As the current UK Operations Director, Dr. Fragkou has demonstrated leadership, strategic acumen, and an unwavering commitment to advancing the company's objectives. In her new capacity, she will play an important role in driving AegirBio's innovative platform development and expediting time-to-market.”
AegirBio is a Swedish diagnostics company founded in 2019 to offer tests to monitor and optimize the dosage of biological drugs via its unique patented technology platform. In June 2020, AegirBio was listed on the Nasdaq First North Growth Market. The company's ambition is, in addition to bringing innovative diagnostic technology to the market, to make diagnostics more accessible, easier to use and to provide accurate and easily transferable results. For more information, see Aegirbio's website www.aegirbio.com
The company's Certified Adviser is Eminova Fondkomission AB | 08-684 211 00 | firstname.lastname@example.org